These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37802153)

  • 1. Neuronal loss and inflammation preceding fibrillary tau pathology in a rat model with early human-like tauopathy.
    Emmerson JT; Malcolm JC; Do Carmo S; Nguyen P; Breuillaud L; Martinez-Trujillo JC; Cuello AC
    Neurobiol Dis; 2023 Oct; 187():106317. PubMed ID: 37802153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive human-like tauopathy with downstream neurodegeneration and neurovascular compromise in a transgenic rat model.
    Emmerson JT; Do Carmo S; Liu Y; Shalhoub A; Liu A; Bonomo Q; Malcolm JC; Breuillaud L; Cuello AC
    Neurobiol Dis; 2023 Aug; 184():106227. PubMed ID: 37454780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy.
    Malcolm JC; Breuillaud L; Do Carmo S; Hall H; Welikovitch LA; Macdonald JA; Goedert M; Cuello AC
    Neurobiol Dis; 2019 Jul; 127():323-338. PubMed ID: 30905766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human tau expression reduces adult neurogenesis in a mouse model of tauopathy.
    Komuro Y; Xu G; Bhaskar K; Lamb BT
    Neurobiol Aging; 2015 Jun; 36(6):2034-42. PubMed ID: 25863528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric alkylpyridinium salts permit intracellular delivery of human Tau in rat hippocampal neurons: requirement of Tau phosphorylation for functional deficits.
    Koss DJ; Robinson L; Mietelska-Porowska A; Gasiorowska A; Sepčić K; Turk T; Jaspars M; Niewiadomska G; Scott RH; Platt B; Riedel G
    Cell Mol Life Sci; 2015 Dec; 72(23):4613-32. PubMed ID: 26070304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in lipid metabolism track with the progression of neurofibrillary pathology in tauopathies.
    Olešová D; Dobešová D; Majerová P; Brumarová R; Kvasnička A; Kouřil Š; Stevens E; Hanes J; Fialová Ľ; Michalicová A; Piešťanský J; Šinský J; Kaňovský P; Friedecký D; Kováč A
    J Neuroinflammation; 2024 Mar; 21(1):78. PubMed ID: 38539208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant Tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology.
    Koss DJ; Robinson L; Drever BD; Plucińska K; Stoppelkamp S; Veselcic P; Riedel G; Platt B
    Neurobiol Dis; 2016 Jul; 91():105-23. PubMed ID: 26949217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease.
    Dengler-Crish CM; Smith MA; Wilson GN
    J Alzheimers Dis; 2017; 55(4):1605-1619. PubMed ID: 27814296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau associated peripheral and central neurodegeneration: Identification of an early imaging marker for tauopathy.
    Marquez A; Guernsey LS; Frizzi KE; Cundiff M; Constantino I; Muttalib N; Arenas F; Zhou X; Lim SH; Ferdousi M; Ponirakis G; Silverdale M; Kobylecki C; Jones M; Marshall A; Malik RA; Jolivalt CG
    Neurobiol Dis; 2021 Apr; 151():105273. PubMed ID: 33482356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model.
    Ponnusamy M; Wang S; Yuksel M; Hansen MT; Blazier DM; McMillan JD; Zhang X; Dammer EB; Collier L; Thinakaran G
    Brain; 2023 Apr; 146(4):1561-1579. PubMed ID: 36059072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking Site-Specific Cleavage of Human Tau Delays Progression of Disease-Related Phenotypes in Genetically Matched Tau-Transgenic Mice Modeling Frontotemporal Dementia.
    Steuer EL; Kemper LJ; Hlynialuk CJW; Leinonen-Wright K; Montonye ML; Lapcinski IP; Forster CL; Ashe KH; Liu P
    J Neurosci; 2022 Jun; 42(23):4737-4754. PubMed ID: 35508385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.
    Boekhoorn K; Terwel D; Biemans B; Borghgraef P; Wiegert O; Ramakers GJ; de Vos K; Krugers H; Tomiyama T; Mori H; Joels M; van Leuven F; Lucassen PJ
    J Neurosci; 2006 Mar; 26(13):3514-23. PubMed ID: 16571759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.
    Rossi F; Geiszler PC; Meng W; Barron MR; Prior M; Herd-Smith A; Loreto A; Lopez MY; Faas H; Pardon MC; Conforti L
    Behav Brain Res; 2018 Feb; 339():140-152. PubMed ID: 29175372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental Pathogenicity of 4-Repeat Human Tau Is Lost with the P301L Mutation in Genetically Matched Tau-Transgenic Mice.
    Gamache JE; Kemper L; Steuer E; Leinonen-Wright K; Choquette JM; Hlynialuk C; Benzow K; Vossel KA; Xia W; Koob MD; Ashe KH
    J Neurosci; 2020 Jan; 40(1):220-236. PubMed ID: 31685653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.
    Stozicka Z; Zilka N; Novak P; Kovacech B; Bugos O; Novak M
    J Neuroinflammation; 2010 Oct; 7():64. PubMed ID: 20937161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy.
    Chang JK; Leso A; Subaiea GM; Lahouel A; Masoud A; Mushtaq F; Deeb R; Eid A; Dash M; Bihaqi SW; Zawia NH
    Curr Alzheimer Res; 2018; 15(7):655-663. PubMed ID: 29357795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Picalm reduction exacerbates tau pathology in a murine tauopathy model.
    Ando K; De Decker R; Vergara C; Yilmaz Z; Mansour S; Suain V; Sleegers K; de Fisenne MA; Houben S; Potier MC; Duyckaerts C; Watanabe T; Buée L; Leroy K; Brion JP
    Acta Neuropathol; 2020 Apr; 139(4):773-789. PubMed ID: 31925534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
    Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P
    Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.